logo
  • About Us
    • Company Overview
    • Vision / Mission / Values
    • Leadership
    • Clinical Advisory Board
    • Partnering
  • Our Approach
    • Technologies
    • Manufacturing
    • Publications
  • Pipeline
    • Pipeline
      • CAR T-cell therapies 
      • mAb
    • Expanded Access
  • Investors
    • Announcements
    • Corporate Governance
    • Corporate Deck & Presentations
      • Webcasts
      • Presentations
    • Financial Reports
    • Listing Documents
    • IR Contact
  • Newsroom
  • Careers
    • Join Us
  • Contact Us
EN 简 繁
  • About Us
    • Company Overview
    • Vision / Mission / Values
    • Leadership
    • Clinical Advisory Board
    • Partnering
  • Our Approach
    • Technologies
    • Manufacturing
    • Publications
  • Pipeline
    • Pipeline
      • CAR T-cell therapies 
      • mAb
    • Expanded Access
  • Investors
    • Announcements
    • Corporate Governance
    • Corporate Deck & Presentations
      • Webcasts
      • Presentations
    • Financial Reports
    • Listing Documents
    • IR Contact
  • Newsroom
  • Careers
    • Join Us
  • Contact Us

Corporate Deck & Presentations

  • Home -
  • Investors -
Corporate Deck
20
Nov 2023
CARsgen Therapeutics Corporate Deck
PDF Icon
Nov 20, 2023
Webcasts
Presentations
13
Nov 2023
2023 SITC | Case Report: Metastatic Gastrointestinal Cancer Patient Responded to Repeated Administration of Anti-Claudin 18.2 CAR-T cells
PDF Icon
Nov 13, 2023
07
Jun 2023
2023 ASCO | Circulating Tumor DNA and Association with CAR T-cell Therapy Response in Gastric and Pancreatic Cancer Patients
PDF Icon
Jun 07, 2023
06
Jun 2023
2023 ASCO | Phase I Trial of Chimeric Anti-GPC3 scFv-CD3ε Engineered T Cells (CT0180) in Patients with Advanced Hepatocellular Carcinoma
PDF Icon
Jun 06, 2023
20
Apr 2023
2023 AACR | CLDN18.2 expression is associated with clinicopathological features and prognosis of Chinese patients with digestive system cancers: a retrospective analysis
PDF Icon
Apr 20, 2023
20
Jan 2023
2023 ASCO GI | A Multicenter, Phase 1 Study of AB011, a Recombinant Humanized Anti CLDN18.2 Monoclonal Antibody (AB011), as Monotherapy and Combined with Capecitabine and Oxaliplatin (CAPOX) in Patients with Advanced Solid Tumors
PDF Icon
Jan 20, 2023
11
Dec 2022
2022 ASH | Phase II Study of Fully Human BCMA-Targeted CAR T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma
PDF Icon
Dec 11, 2022
  • 1
  • 2
Wechat
qr
Linkedin
  • About Us
  • Company Overview
  • Vision / Mission / Values
  • Leadership
  • Clinical Advisory Board
  • Partnering
  • Our Approach
  • Technologies
  • Manufacturing
  • Publications
  • Pipeline
  • Pipeline
  • Expanded Access
  • Investors
  • Announcements
  • Corporate Governance
  • Corporate Deck & Presentations
  • Financial Reports
  • Listing Documents
  • IR Contact
  • Newsroom
  • Careers
  • Join Us
  • Contact Us
Privacy Policy Terms of Use Developed by Euroland IR
Copyright ©2021-2023 CARsgen Therapeutics Holdings Limited